Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

BILN 2061 is a novel, specific hepatitis C virus (HCV) NS3 serine protease inhibitor discovered by Boehringer Ingelheim that has shown potent activity against HCV replicons in tissue culture and is currently under clinical investigation for the treatment of HCV infection. The poor fidelity of the HC...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Lu, Liangjun, Pilot-Matias, Tami J., Stewart, Kent D., Randolph, John T., Pithawalla, Ron, He, Wenping, Huang, Peggy P., Klein, Larry L., Mo, Hongmei, Molla, Akhteruzzaman
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2004
Assuntos:	Antiviral Agents
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC415624/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15155230/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.6.2260-2266.2004
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!